Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
265
mi
from 02139
Harleysville, PA
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
265
mi
from 02139
Harleysville, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
252
mi
from 02139
Holland, PA
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
252
mi
from 02139
Holland, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
326
mi
from 02139
Jersey Shore, PA
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
326
mi
from 02139
Jersey Shore, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
249
mi
from 02139
Penndel, PA
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
249
mi
from 02139
Penndel, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
269
mi
from 02139
Philadelphia, PA
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
269
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
391
mi
from 02139
Tipton, PA
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
391
mi
from 02139
Tipton, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
822
mi
from 02139
Charleston, SC
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
822
mi
from 02139
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
816
mi
from 02139
Mount Pleasant, SC
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
816
mi
from 02139
Mount Pleasant, SC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
866
mi
from 02139
Crossville, TN
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
866
mi
from 02139
Crossville, TN
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
730
mi
from 02139
Kingsport, TN
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
730
mi
from 02139
Kingsport, TN
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
1574
mi
from 02139
Fort Worth, TX
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
1574
mi
from 02139
Fort Worth, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
1569
mi
from 02139
Haltom City, TX
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
1569
mi
from 02139
Haltom City, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
1769
mi
from 02139
San Antonio, TX
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
1769
mi
from 02139
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
850
mi
from 02139
Kenosha, WI
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM2)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
850
mi
from 02139
Kenosha, WI
Click here to add this to my saved trials
Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia
Status: Enrolling
Updated:  11/27/2012
Biofortis Clinical Research
864
mi
from 02139
Addison, IL
Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia
Status: Enrolling
Updated: 11/27/2012
Biofortis Clinical Research
864
mi
from 02139
Addison, IL
Click here to add this to my saved trials
Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk
Home-based Exercise for Management of HIV-associated Cardiovascular Disease
Status: Enrolling
Updated:  2/18/2013
The Citadel
818
mi
from 02139
Charleston, SC
Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk
Home-based Exercise for Management of HIV-associated Cardiovascular Disease
Status: Enrolling
Updated: 2/18/2013
The Citadel
818
mi
from 02139
Charleston, SC
Click here to add this to my saved trials
Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk
Home-based Exercise for Management of HIV-associated Cardiovascular Disease
Status: Enrolling
Updated:  2/18/2013
University of South Carolina
815
mi
from 02139
West Columbia, SC
Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk
Home-based Exercise for Management of HIV-associated Cardiovascular Disease
Status: Enrolling
Updated: 2/18/2013
University of South Carolina
815
mi
from 02139
West Columbia, SC
Click here to add this to my saved trials
Lovaza Mechanisms of Action
Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects
Status: Enrolling
Updated:  2/21/2013
Brigham and Women's Hosp
2
mi
from 02139
Boston, MA
Lovaza Mechanisms of Action
Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects
Status: Enrolling
Updated: 2/21/2013
Brigham and Women's Hosp
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
A Two-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003 in Healthy Subjects
Status: Enrolling
Updated:  3/28/2013
Medpace CPU
735
mi
from 02139
Cincinnati, OH
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
A Two-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003 in Healthy Subjects
Status: Enrolling
Updated: 3/28/2013
Medpace CPU
735
mi
from 02139
Cincinnati, OH
Click here to add this to my saved trials
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Statins in Children With Type 1 Diabetes: Effects on Metabolism, Inflammation and Endothelial Function
Status: Enrolling
Updated:  5/19/2013
Alfred I duPont Hospital
294
mi
from 02139
Wilmington, DE
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Statins in Children With Type 1 Diabetes: Effects on Metabolism, Inflammation and Endothelial Function
Status: Enrolling
Updated: 5/19/2013
Alfred I duPont Hospital
294
mi
from 02139
Wilmington, DE
Click here to add this to my saved trials
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Statins in Children With Type 1 Diabetes: Effects on Metabolism, Inflammation and Endothelial Function
Status: Enrolling
Updated:  5/19/2013
Nemours Children's Clinic
1017
mi
from 02139
Jacksonville, FL
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Statins in Children With Type 1 Diabetes: Effects on Metabolism, Inflammation and Endothelial Function
Status: Enrolling
Updated: 5/19/2013
Nemours Children's Clinic
1017
mi
from 02139
Jacksonville, FL
Click here to add this to my saved trials
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Statins in Children With Type 1 Diabetes: Effects on Metabolism, Inflammation and Endothelial Function
Status: Enrolling
Updated:  5/19/2013
Nemours Children's Clinic-Jefferson
268
mi
from 02139
Philadelphia, PA
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Statins in Children With Type 1 Diabetes: Effects on Metabolism, Inflammation and Endothelial Function
Status: Enrolling
Updated: 5/19/2013
Nemours Children's Clinic-Jefferson
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
Effects of Black Tea Intake on Serum Lipids
Effects of Black Tea Intake on Serum Lipids in Mildly Hypercholesterolemic Adults A Randomized Diet-controlled Crossover Trial
Status: Enrolling
Updated:  6/17/2013
General Clinical Research Center, University of Minnesota
1117
mi
from 02139
Minneapolis, MN
Effects of Black Tea Intake on Serum Lipids
Effects of Black Tea Intake on Serum Lipids in Mildly Hypercholesterolemic Adults A Randomized Diet-controlled Crossover Trial
Status: Enrolling
Updated: 6/17/2013
General Clinical Research Center, University of Minnesota
1117
mi
from 02139
Minneapolis, MN
Click here to add this to my saved trials
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Status: Enrolling
Updated:  6/25/2013
Massachusetts General Hospital
1
mi
from 02139
Boston, MA
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Status: Enrolling
Updated: 6/25/2013
Massachusetts General Hospital
1
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Bioavailability of EPA and DHA From Two Dietary Supplements
A Randomized, Controlled, Crossover Study to Evaluate the Acute and Subchronic Bioavailability of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) From Two Dietary Supplements in Men and Women With Mildly Elevated Triglycerides
Status: Enrolling
Updated:  7/23/2013
Biofortis
864
mi
from 02139
Addison, IL
Bioavailability of EPA and DHA From Two Dietary Supplements
A Randomized, Controlled, Crossover Study to Evaluate the Acute and Subchronic Bioavailability of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) From Two Dietary Supplements in Men and Women With Mildly Elevated Triglycerides
Status: Enrolling
Updated: 7/23/2013
Biofortis
864
mi
from 02139
Addison, IL
Click here to add this to my saved trials
Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals
Effects of a Modified Lower Carbohydrate, Higher Fat DASH Diet Plan on Plasma Lipids, Lipoprotein Particle Size, and Blood Pressure in Healthy Adults
Status: Enrolling
Updated:  7/30/2013
Cholesterol Research Center, Children's Hospital Oakland Research Institute
2680
mi
from 02139
Berkeley, CA
Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals
Effects of a Modified Lower Carbohydrate, Higher Fat DASH Diet Plan on Plasma Lipids, Lipoprotein Particle Size, and Blood Pressure in Healthy Adults
Status: Enrolling
Updated: 7/30/2013
Cholesterol Research Center, Children's Hospital Oakland Research Institute
2680
mi
from 02139
Berkeley, CA
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Farmville Internal Medicine
mi
from 02139
Farmville, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Farmville Internal Medicine
mi
from 02139
Farmville, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Mark R. Cervi
mi
from 02139
Greenville, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Mark R. Cervi
mi
from 02139
Greenville, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Physicians East, Quadrangle Medical Specialists
mi
from 02139
Greenville, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Physicians East, Quadrangle Medical Specialists
mi
from 02139
Greenville, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Carolina East Family Medicine
576
mi
from 02139
Greenville, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Carolina East Family Medicine
576
mi
from 02139
Greenville, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Eastern Carolina Physicians
mi
from 02139
Kinston, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Eastern Carolina Physicians
mi
from 02139
Kinston, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Natalie A Doyle, MD PA
586
mi
from 02139
Wilson, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Natalie A Doyle, MD PA
586
mi
from 02139
Wilson, NC
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
1033
mi
from 02139
Muscle Shoals, AL
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
1033
mi
from 02139
Muscle Shoals, AL
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
1015
mi
from 02139
Jacksonville, FL
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
1015
mi
from 02139
Jacksonville, FL
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
1256
mi
from 02139
Miami, FL
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
1256
mi
from 02139
Miami, FL
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
1110
mi
from 02139
Winter Park, FL
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
1110
mi
from 02139
Winter Park, FL
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
1247
mi
from 02139
Kansas City, KA
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
1247
mi
from 02139
Kansas City, KA
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
821
mi
from 02139
Louisville, KY
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
821
mi
from 02139
Louisville, KY
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
127
mi
from 02139
Auburn, ME
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
127
mi
from 02139
Auburn, ME
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
608
mi
from 02139
Raleigh, NC
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
608
mi
from 02139
Raleigh, NC
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
608
mi
from 02139
Raleigh, NC
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
608
mi
from 02139
Raleigh, NC
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
735
mi
from 02139
Cincinnati, OH
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
735
mi
from 02139
Cincinnati, OH
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
735
mi
from 02139
Cincinnati, OH
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
735
mi
from 02139
Cincinnati, OH
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
735
mi
from 02139
Cincinnati, OH
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
735
mi
from 02139
Cincinnati, OH
Click here to add this to my saved trials
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  10/8/2013
Pfizer Investigational Site
2279
mi
from 02139
Gilbert, AZ
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 10/8/2013
Pfizer Investigational Site
2279
mi
from 02139
Gilbert, AZ
Click here to add this to my saved trials
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  10/8/2013
Pfizer Investigational Site
392
mi
from 02139
Washington,
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 10/8/2013
Pfizer Investigational Site
392
mi
from 02139
Washington,
Click here to add this to my saved trials
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  10/8/2013
Pfizer Investigational Site
1202
mi
from 02139
Atlantis, FL
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 10/8/2013
Pfizer Investigational Site
1202
mi
from 02139
Atlantis, FL
Click here to add this to my saved trials
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  10/8/2013
Pfizer Investigational Site
350
mi
from 02139
Baltimore, MD
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 10/8/2013
Pfizer Investigational Site
350
mi
from 02139
Baltimore, MD
Click here to add this to my saved trials
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  10/8/2013
Pfizer Investigational Site
546
mi
from 02139
Akron, OH
Atorvastatin Three Year Pediatric Study
A Three Year, Prospective, Open-Label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 10/8/2013
Pfizer Investigational Site
546
mi
from 02139
Akron, OH
Click here to add this to my saved trials